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Parkinson's diseasensport chain (ETC) deﬁciencies are thought to underlie defects in energy
metabolism and have been implicated in the neurodegenerative process. In particular, reductions in complex
I activities in Parkinson's disease are thought to cause bioenergetic dysfunction with subsequent
degeneration of dopaminergic neurons. In terms of bioenergetics and assessing ETC-related problems in
the brain, the presence of heterogeneous mitochondria has complicated matters as isolated non-synaptic
mitochondria have different energy thresholds and ﬂux control coefﬁcients compared to isolated
mitochondria of synaptic origin. The molecular mechanisms that underlie complex I deﬁciencies in the
parkinsonian brain are unknown and are the source of intensive research. This review explores the
relationship between complex I activity and energy metabolism in the brain as well as the nature of the
complex I defect.
© 2008 Elsevier B.V. All rights reserved.1. Complex I and Parkinson's disease
Mitochondrial dysfunction is characteristic of several neurodegen-
erative disorders [1] and also of the aging process [2]. Parkinson's
disease is characterized by a selective decrease in dopamine in the
striatum caused by a degeneration of dopaminergic neurons in the zona
compacta of the substantia nigra [3,4]. Complex I (NADH:ubiquinone
oxidoreductase, EC 1.6.5.3) activity is reduced by 35–40% in substantia
nigra homogenates in postmortem studies of Parkinson's disease
patients [5,6,7]. However, recent evidence has suggested that a complex
I deﬁciency may be widespread in the parkinsonian brain, as the
occurrenceof amutation inmitochondrialDNA in idiopathic Parkinson's
disease [8], and an associated reduction in complex I activity in
mitochondria from the frontal cortex [9,10] have been reported. This
evidence supports the hypothesis that complex I deﬁciency plays a
central role in the initial etiology of the disease [11,12,13].
The cause of the complex I deﬁciency is unknown, however, follow-
up studies on Parkinson's disease patients injected with fetal tissue
enriched in dopaminergic cells shows that an environment exists in
the parkinsonian brain that induces the classical disease pathology in
the transplanted cells [14]. It is not known if complex I activity in these
cells is reduced following transplantation or if a complex I defect in
surrounding cells induces the neurodegenerative condition. However,
in certain in vitro models of the nerve terminal (synaptosomes) it has
been shown that complex I deﬁciencies can result in large amounts
of glutamate being released that may be potentially excitotoxic to
surrounding cells [15]. Dopamine neurons are known to possess
glutamate receptors, therefore, existing complex I deﬁciencies thatl rights reserved.lead to increased glutamate release may increase excitotoxic events in
the parkinsonian brain.
2. Flux control analysis of oxidative phosphorylation in brain
mitochondria
Analysis of complex I activities in mitochondria with the help of
metabolic control analysis (MCA) has revealed some interesting
ﬁndings concerning mitochondrial heterogeneity in the brain. When
the relative contribution of individual mitochondrial respiratory chain
complexes to the control of NAD-linked substrate (glutamate and
malate) oxidative phosphorylation in mitochondria from various rat
brain regions was investigated, it was found that complex I possessed
a higher control over oxidative phosphorylation in synaptic mito-
chondria than in non-synaptic mitochondria [16–18]. As shown in
Table 1, when rotenone, myxothiazol and KCN were used to titrate out
complexes I, III and IV activities, respectively, while measuring
oxidative phosphorylation parameters, the highest ﬂux control
coefﬁcients were found with complex I in mitochondria of synaptic
origin. It is unclear if the complex I ﬂux control difference is due to a
differing subunit compliment in both types of mitochondria at
biogenesis or loss of function in mitochondria as they travel to the
nerve terminal and subsequently synthesize the majority of ATP
required for normal synaptic function.
Other studies have shown that respiratory chain complexes are
involved in the control of mitochondrial respiration and that the
distribution of the control indices of these complexes may be
different, depending on the tissue from which the mitochondria
were isolated [19–22]. Brain mitochondria show lowest oxidative
phosphorylation efﬁciency with complex I substrates, measured as
P/O ratios, compared to mitochondria from heart and liver [23].
Table 1
Flux control coefﬁcients for ETC complexes I, III and IV in brain mitochondria
Whole brain non-synaptic
mitochondria
Whole brain synaptic
mitochondria
CA1 non-synaptic
mitochondria
Cortex non-synaptic
mitochondria
CA1 synaptic
mitochondria
Cortex synaptic
mitochondria
Complex I 0.14 0.29 0.13 0.11 0.30 0.32
Complex III 0.15 0.20 – – – –
Complex IV 0.24 0.13 0.22 0.20 0.15 0.14
Data taken from 16, 17 and 18.
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all the control coefﬁcients in any pathway is equal to unity; so in the
case of the three complexes described in Table 1 the total is 0.62 for
synaptic mitochondria from whole brain. Other systems known to
contribute to the control of mitochondrial respiration are; adenine
translocator [19,25], phosphate carrier and calcium [26,27], proton
leak [28], ADP-regenerating system and dicarboxylate carrier [19].
Using a top-down analysis of synaptosomal bioenergetics, it was
found that the substrate oxidation system, phosphorylation system
and proton leak had ﬂux control coefﬁcients of 0.71, 0.27 and 0.02,
respectively, and that uncoupled oxygen respiration rates were
signiﬁcantly lower in synaptosomes fromyoung rats when compared
to synaptosomes from old rats [29].
3. Energy thresholds in brain mitochondria
While metabolic control analysis has provided insight into the
control that ETC complexes have over oxidative phosphorylation, the
use of speciﬁc inhibitors has also enabled researchers to model the
effects of substantial ETC deﬁciencies on respiration rates and ATP
synthesis in the mitochondrion. This concept of mitochondrial energy
thresholds has been identiﬁed in many tissues [30] and has been
associated with thresholds at the transcriptional and translational
levels.
In preparations of brain mitochondria, titration of complex I, III, and
IV activities with speciﬁc inhibitors generated threshold curves that
showed the extent towhich a complex activity could be inhibited before
causing impairment of mitochondrial energy metabolism (Table 2). For
mitochondria of non-synaptic origin, itwas found that complex I, III, and
IV activities need to be decreased by approximately 60, 70, and 60%,
respectively, before major changes in rates of oxygen consumption and
ATP synthesis were observed. Similar thresholds were observed for
complexes III and IV in synapticmitochondria suggesting that they have
large reserves of activity and must be inhibited to a large extent before
oxidative phosphorylation is severely compromised. These threshold
effects are not restricted to brain mitochondria and have been observed
in rat muscle mitochondria for complex IV [31] and III [32], where the
activity must be reduced by approximately 70 and 60%, respectively,
before major changes in oxidative phosphorylation occur.
However, the energy threshold for complex I is reduced to 25% in
mitochondria of synaptic origin. These results suggest that, in mito-
chondria of synaptic origin, complex I activity has a major control of
oxidative phosphorylation, such that when a threshold of 25% in-
hibition is exceeded, energymetabolism is severely impaired, resulting
in a reduced synthesis of ATP. The signiﬁcance of this ﬁnding is im-
portant in that the reported decrease of 40% in complex I activity in
Parkinson's disease patients [5–7] would extrapolate to a 35–40%
inhibition of ATP synthesis and respiration in the synaptic mitochon-Table 2
Thresholds for ETC complex control of respiration in brain mitochondria
Whole brain non-synaptic
mitochondria
Whole brain synaptic
mitochondria
CA1 n
mitoch
Complex I 72 25 60
Complex III 70 80 Nd
Complex IV 60 70 60
Data taken from 16, 17 and 18.dria model. There is no information on the energy thresholds for ETC
complexes inside intact synaptosomes, however, theymaybe expected
to be different considering glucose and lactate are substrates for nerve
terminal bioenergetics and in situ mitochondria respire somewhere
between state III and state IV.
Titration of complex I activity in synaptosomes, followed by depolar-
ization with KCl or 4-aminopyridine, reduces ATP concentrations and
leads to signiﬁcant amounts of Ca2+-independent glutamate release [15].
Extrapolation of these results to Parkinson's disease suggests that a 40%
decrease in complex I activity in the substantia nigra could induce excess
release of excitotoxic glutamate following action potentials. In addition,
reductionof complex I activities in synaptosomes from18monthold rats
resulted in a faster release of glutamate, compared to synaptosomes
from 6 month old rats, indicating that nerve terminals from aged
animals as opposed to younger rats may be more susceptible to mito-
chondrial dysfunction [33].
Threshold effects have been described in mitochondrial diseases
[30] and may be related to the balance between normal and mutant
mtDNA. If the expression of this heteroplasmy of mtDNA is at the level
of a given respiratory complex enzyme, then these may reinforce
threshold effects observed in mitochondrial metabolism. Whether or
not respiratory chain complex activities would be reduced sufﬁciently
to seriously compromise oxidative phosphorylation would depend on
the type of mitochondria affected. Due to the heterogeneous nature of
brain mitochondria in which complex I thresholds in synaptic mito-
chondria are different to those innon-synapticmitochondria [16,17,18],
it may be possible that degeneration preferentially occurs in synapses.
4. Glutathione and complex I activity
In addition to a reduction in complex I activity in Parkinson's disease,
decreased levels of glutathione have also been found in postmortem
examination of the substantia nigra [34–36]. This suggests an increased
oxidative stress involvement in Parkinson's disease, as glutathione is
present in millimolar concentrations in mammalian cells and is
considered to be a major antioxidant in the brain, capable of protecting
cells from damage caused by free radicals [37].
In order to observe the consequences of glutathione depletion on
mitochondrial function and to partly imitate that which is reported to
occur in idiopathic Parkinson's disease, the catecholaminergic PC12
cell line was depleted of glutathione using the gamma glutamyl-
transferase inhibitor, L-BSO, and the effect on the complex I threshold
was measured. As shown in Fig. 1, oxygen respiration exhibited a
threshold effect at 30–40% inhibition of complex I activity, suggesting
that PC12 cell mitochondria have a different complex I threshold to
that found in synaptic and non-synaptic mitochondria. Similar
thresholds for complex I activity have been reported in other cell
lines, possibly reﬂecting the fact that mitochondria respiring in situ, inon-synaptic
ondria
Cortex non-synaptic
mitochondria
CA1 synaptic
mitochondria
Cortex synaptic
mitochondria
60 25 25
Nd Nd Nd
60 60 60
Fig. 1. Depletion of glutathione abolishes the complex I threshold in PC12 cells. PC12
cells were incubated for 18 h in the presence (○) and absence (•) of the glutathione-
depleting compound, L-BSO. The percent inhibition of complex I activity was calculated
and plotted against respiration rates (data taken from 18).
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mitochondria. However, following the depletion of glutathione in
PC12 cells the complex I threshold effect was abolished (Fig. 1).
The mechanism by which GSH causes removal of the complex I
threshold in mitochondria is not known, however, glutathione is an
antioxidant which protects mitochondria from lipid peroxidation [38] and
when depleted may render complex I susceptible to free radical attack.
Previous studies have shown that depletion of GSH induces enlargement
and degeneration of brain mitochondria [39] as well as a decrease in
complex IV activity in puriﬁed brain mitochondrial preparations [40].
Treatment of rat brain primary cultures with L-BSO caused decreases in
complex I activity, complex II–III activityandcomplex IVactivityof34%,60%
and 41%, respectively [41] however when similar glutathione experiments
were done with rat brain primary astrocytes, complex I activity was
increased 2-fold [42] and 4-fold [43]. These results suggest that, under
conditions of GSH depletion, neurons are more vulnerable to metabolic
insult,which results in a compromise inmitochondrial energymetabolism.
The ﬁnding of a reduced complex I threshold in conjunctionwith a
constitutive metabolic deﬁciency in dopaminergic neurons from the
substantia nigra [44,45] may predispose these neurons to apoptotic or
necrotic mechanisms. There is evidence that mitochondrial complex I
dysfunction is a consequence of stress oxidation of critical thiol groups
in the enzyme [46,47]. Similarly, reversible glutathionylation of com-
plex I increases mitochondrial superoxide formation [48]. Thus, the
implications for these results might be extendable to complex I and
glutathione abnormalities that are seen in Parkinson's disease, and
may underlie selective neuronal degeneration.
5. Cause of complex I deﬁciency — role for assembly?
As stated above, the cause of complex I deﬁciency in Parkinson's
disease is unknown and little information is available on the nature of
complex I assembly in brain mitochondria. The possibility that ab-
normal assembly mechanisms in the brain may exist requires further
consideration and the literature on complex I structure and assembly
in mitochondria from other tissues provides a starting point. Mam-
malian complex I is composed of 45 different subunits that assemble
together at the inner mitochondrial membrane [49]. The assembly of
this complex is complicated partly because of its large size and partly
because its regulation by two genomes. Seven of the complex Isubunits are encoded by the mitochondrial (mt) DNA and the
remaining by the nuclear genes. The nuclear DNA-encoded subunits
are synthesized in the cytosol and are imported into the organelle. The
mtDNA-encoded subunits must assemble with the nuclear encoded
subunits to generate the functional holoenzyme [49–53]. The multi-
meric holoenzyme is L-shaped with a hydrophobic membrane arm
embedded in themitochondrial innermembrane and perpendicular to
it is a hydrophilic peripheral armwhich protrudes into the mitochon-
drial matrix [54,55]. The 14 most conserved subunits (which form the
fully functional complex I in bacteria) form the ‘core’ structure. The
‘core’ structure is also considered to be theminimal structure required
for the functionality of the enzyme [56]. The function of most of the
additional 31 supernumerary subunits is not yet clear but some are
hypothesized to stabilize or to protect the complex from ROS damage.
Several of these subunits may have an additional function. For
example, the subunits NDUFA13 [also known as GRIM-19] and
NDUFS1 have been implicated to have a role in apoptosis [57,58].
Assembly of complex I subunits is an intricately elaborate process
which has been studied in several organisms of different evolutionary
lineages. Studies in model organisms as simple as the bacteria
[Escherichia coli] and the green algae [Chlamydomonas reinhardtii] to
more complex eukaryotes like the fungus [Neurospora crassa], higher
plants [Zea mays, Arabidopsis thaliana] and mammals has outlined the
basic process of complex I assembly. The main consensus ﬁndings of
these studies are — a] complex I assembly is not sequential but is
modular which means that the subunits are not incorporated one by
one into the complex but instead several discrete assembly inter-
mediates are assembled independently and are joined in several steps
to form a peripheral arm and a membrane arm; b] peripheral arm can
be assembled independently of the membrane arm; c] sub-assemblies
of the nuclear DNA-encoded subunits and the mtDNA-encoded
subunits can be formed independently; d] in eukaryotes, a nuclear
DNA-encoded scaffold of peripheral arm is attached to the inner
membranewhere it joins to the membrane arm intermediate [59–62].
There are many different models proposed for mammalian
complex I assembly and even though there are differences between
these models, a recent review draws out a general concept for
complex I assembly [63]. According to a generalized model, NuoC and
NuoD (bacterial homologues of NDUFS2 and NDUFS3) form the
starting point of the peripheral arm assembly. Addition of NuoB, I, E, F
and G (bacterial homologues of NDUFS7, NDUFS8, NDUFV1, NDUFV2
and NDUFS1) result in a large peripheral arm intermediate
(~600 kDa), which is then anchored to the mitochondrial inner
membrane with the help of its transporter subunits NuoH [bacterial
homologue of ND1]. This membrane anchored peripheral complex
extends by combining to the highly conserved hydrophobic mem-
brane arm intermediate and results in holo-complex I (~950 kDa).
Complex I assembly is a highly dynamic process in which existing
and newly synthesized subunits can be exchanged. A recent paper by
Lazarou et al. [64] demonstrates that nuclear DNA-encoded subunits of
complex I are incorporated into the complex much faster than the
mtDNA-encoded subunits even though the nuclear DNA-encoded
subunits were not rate limiting for complex I assembly. This observa-
tion leads to a suggestion that the newly synthesized nuclear DNA-
encoded subunits are exchanged with the assembled ones. The authors
speculate that the complex I transitions between assembled and inter-
mediate forms may enable a mechanism that facilitates the turnover of
subunits, someofwhichmaybeoxidatively damaged.Given the fact that
a number of complex I subunits become oxidatively damaged in the
brains of patients with Parkinson's disease [9], it is possible that an
underlying basis of the disease is a decreased rate of protein import and/
or assembly which slows the exchange rate of pre-existing complex I
subunits for newly imported ones. This may lead to increased oxidative
damage, complex I deﬁciency and subsequent disease.
The complex I assembly process is even more complicated by the
fact that in addition to a perfect assembly, the nuclear transcription,
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into the mitochondria, insertion into the membrane, stabilization and
activation of the enzyme, every step requires a precise coordination.
With this perspective the importance of chaperone proteins becomes
evident. Chaperones are a family of proteins that assist the correct
assembly of other polypeptide containing structures in vivo, but are
not a component of the ﬁnal functional structure. Examples of
mutations in the assembly chaperones that lead to the inability to
assemble a properly functioning complex I and thus lead to complex I
deﬁciency diseases, have been reported [65].
In contrast to the numerous complex III and complex IV assembly
chaperones known, so far only three candidate complex I assembly
factors have been found. Two of these, the NDUFAF1 (the human
homologue of fungal protein CIA30) and a paralogue of complex I
subunit B17.2 known as B17.2-like (B17.2L) are well established and
well studied complex I assembly chaperones. Ecsit (Evolutionary
Conserved Signaling Intermediate in Toll pathways) is yet another
recent addition to the list. The conventional role of this signaling
intermediate in the Toll-pathway is inpassing of amessage from ligand
activated plasma membrane receptor to transcription of pro-inﬂam-
matory genes. But intriguingly it has a role in mitochondrial complex I
assembly [66]. This exciting ﬁnding leads to an interesting speculation
that Ecsit may extend the cascade of immune response to mitochon-
drial level and may affect cellular energy production upon inﬂamma-
tion. A numberof studies have linked inﬂammation to sporadic cases of
neurodegeneration and mitochondria are known to be damaged by
inﬂammatory processes. A very relevant example is provided by the
HIV-1 induced T-cell apoptosis where viral infection downregulates
the expression of complex I subunit NDUFA6 [67]. This subunit is
important for complex I assembly and it associates with a 650 kDa
intermediate prior to the formation of a fully assembled holoenzyme
and reduction in its level would result in reduced level of functional
complex I. Thus, viral infection manipulates complex I assembly
process, reduces the cellular energy level to its own beneﬁt and ﬁnally
leads to the apoptosis of the T-cell. A similar link between inﬂamma-
tion and neurodegeneration is yet to be investigated and established.
6. Complex I and supercomplexes
Although there is awealth of knowledge available on the structure of
the individual electron transport chain complexes, their supramolecular
organization into ‘respirasomes’ is relatively an under-studied area. This
is mainly because these complexes are functionally active even when
isolated as individual complexes and the detergent used to solubilize
them out of the inner membrane partially destroys the supramolecular
assembly. Previously, two models have been proposed for the organiza-
tion of the respiratory chain. The random collision model or the ‘ﬂuid
state’ model, proposed by Hackenbrock [68] was accepted by many
investigators in the ﬁeld. According to the model complex I–IV moves
freely by lateral diffusion in the inner mitochondrial membrane and
electron transfer is based on random collisions of the involved
components. Ubiquinone and cytochrome c have a diffusion rate that is
faster than the bulkier complexes. This model was backed by studies on
mobilityof the complexes and subsequently supportedbykinetic analysis
of steadystate respirationand saturationkinetics of electron transfer [69].
In contrast, several other lines of evidence support the ‘solid state’
model which promotes the idea of preferential associations and spe-
ciﬁc aggregation of the complexes: a) a mild puriﬁcation and separa-
tion protocol (BN-PAGE) and immunoprecipitation results in co-
puriﬁcation of more than one complex [70,71]; b) ﬂux control
experiments favours the supramolecular organization of the com-
plexes rather than their individual occurrence [72]; c) organization
into supercomplexes leads to improved stabilization of individual
complexes [73]; d) mutations leading to a loss of complex III prevents
supercomplex formation and leads to a secondary loss of complex I
[74]; e) the complexes are present in vivo at deﬁned stoichiometries[75]; f) single particle electronmicroscopy has elucidated the 3Dmaps
of the supercomplexes [76,77]. Inspite of the ongoing debate, the solid
but dynamic model of the electron transport chain complex organi-
zation is more widely accepted now.
The supercomplexes have been identiﬁed and characterized from a
broad range of organisms using BN-PAGE and sucrose gradient
centrifugation. The supercomplex I–III, characterized in Arabidopsis,
consists of complex I and dimeric complex III. The supercomplex III–IV
consisting of dimeric complex III and one to two copies of monomeric
complex IV, has been characterized in yeast. The largest supercomplex
from bovine heart, consists of complex I plus complex III2 plus
complex IV1–4 and is termed the ‘respirasome’. The supramolecular
organization of the oxidative phosphorylation complexes into respira-
somes may be of functional importance as they may enhance electron
transfer rates, reduce diffusion distances of substrates by substrate
channeling and increase the stability of the complexes. Although little
is known about supercomplexes in the brain, the different energy
thresholds and ﬂux control coefﬁcients described above may be
related to a range of supercomplex formations in brain mitochondria.
The formation of supercomplexes I–III is facilitated by lipid com-
ponent in the inner membrane. All puriﬁed preparations of mitochon-
drial electron transfer complexes are isolated as lipoprotein complexes.
Complete extraction of phospholipids from these lipoprotein complexes
reveal that cardiolipin, phosphatidylcholine and phosphatidylethano-
lamine are the predominant components. These phospholipids are not
only responsible for dispersive solubilization and catalytic effect
(speciﬁcally brought about by cardiolipin), but maybe responsible for
providing a sufﬁciently lipophilic environment for the interaction of the
oxidative phosphorylation components. The absolute requirement
of cardiolipin for complex I and complex III activities suggest that
this phospholipid plays a crucial role in the coupled electron transfer
[78–80]. Recently using the cardiolipin lacking mutant yeast, it was
demonstrated that 90% of the individual homodimers of complex III and
complex IV were not organized into supercomplexes [81].
Other papers report that cardiolipin is important for the stability of
supercomplexes and exposure of mitochondria to reactive oxygen
species (ROS) can damage cardiolipin by the process of lipid peroxida-
tion [82–83]. Although no direct evidence exists yet, the assumption
that lipid peroxidation by ROS may disrupt the supercomplexes has
pathological implications. This may be an underlying cause of aging
and age-related disorders like Parkinson's disease, where damage by
ROS and a reduction in mitochondrial energetic capacity due to
dissociation of supercomplexes may be responsible for the deleterious
consequences. A recent paper reported amutation in human TAZ gene
associated with Barth Syndrome [84]. These patients show mitochon-
drial morphological abnormalities and respiratory chain dysfunction.
Patients with Barth syndrome lack the TAZ gene product, Tafazzin
[a putative phospholipid acyltransferase], and exhibit defects in
cardiolipin. Using BN-PAGE the authors demonstrated that super-
complex I/III2 and supercomplex I/III2/IV were more labile in
lymphoblasts from Barth syndrome patients. The level of complex I
holoenzymewas also reduced. These interesting observations warrant
investigation of ROS-induced damage to phospholipids, genetic
defects in phospholipid metabolism and supercomplex instability as
theymay reveal new information onmechanisms that underlie neuro-
degenerative diseases.
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